Imagine the body's natural healing process for a wound, but applied to vaginal tissue that has become thin and dry. This technology fixes the underlying cause of dryness without using hormones, which many women cannot take. It works like a monthly home-care routine that restores moisture and elasticity.
Millions of women, including breast cancer survivors, suffer from vaginal atrophy but reject current hormone-based treatments due to safety concerns or medical contraindications.
A hormone-free medical device for home use and a supporting digital ecosystem including an app and subscription model for monitoring.
If you are a FemTech manufacturer dealing with the 3.6m patients who reject current treatments — this project developed a hormone-free medical device that provides a safe, affordable alternative for home use.
If you are a clinic dealing with the 70% of breast cancer survivors who suffer from vaginal atrophy due to chemotherapy — this project developed a targeted therapy that treats the condition without interfering with cancer-blocker drugs.
If you are a platform provider dealing with chronic condition monitoring — this project developed a subscription model and app-integrated treatment that allows for remote prescription renewals and patient reviews.
Based on available project data, the solution is described as 'affordable' and utilizes a subscription model to improve healthcare outcomes.
Based on available project data, the project focuses on a medical device for home administration, though specific manufacturing capacity numbers are not provided.
The project involved filing further foreground IP with new inventions for other women's health applications during the 24-month development period.
It is designed to be clinically prescribed in an outpatient setting, with the patient self-administering the therapy monthly at home via a 15-minute session.
The project worked to generate clinical data to drive adoption at US trial sites and de-risk EU clinical trials in the year following the EIC funding.
The project is led by a single SME, AVETA MEDICAL LIMITED from Ireland. With a 100% industry ratio and no university or research partners, the consortium is lean and focused entirely on commercialization and clinical translation rather than basic research.
Contact AVETA MEDICAL LIMITED in Ireland for licensing and clinical trial data.
Contact SciTransfer to explore partnership opportunities with AVeta Medical.
